mango
Senior Member
- Messages
- 905
"On March 8, 2016, the Pharmacy Compounding Advisory Committee will discuss six bulk drug substances nominated for inclusion on the section 503A bulk drug substances list. FDA will discuss the following nominated bulk drug substances: Quinacrine hydrochloride, boswellia, aloe vera 200:1 freeze dried, D-ribose, chondroitin sulfate, and acetyl-L-carnitine. D-ribose has been nominated for inclusion on the list of bulk drug substances for use in compounding for use in the treatment of heart disease and myalgic encephalomyelitis/chronic fatigue syndrome.
Additional information can be found at the following web link:"
http://www.fda.gov/AdvisoryCommitte...acyCompoundingAdvisoryCommittee/ucm486094.htm
Additional information can be found at the following web link:"
http://www.fda.gov/AdvisoryCommitte...acyCompoundingAdvisoryCommittee/ucm486094.htm